

## **Unmet Need Overview**

**Quick Start Guide** 

February 2022

#### What is Unmet Need?


Unmet Need is part of a suite of Clarivate DRG applications for the Biopharma and Biotech industries supported by detailed primary and secondary research. Product highlights include:

- ✓ Identify areas of unmet need and direct your clinical development strategy to the areas with the greatest opportunity based on surveys of US and EU physician specialists and in-house experts
- ✓ Geographic Coverage: US, France, Germany, UK
- $\checkmark$  Stated vs. derived importance of product attributes on prescribing behavior
- ✓ Assessment of drug performance on treatment drivers and goals
- ✓ Physician perception of unmet needs in indication and related indications
- ✓ Analysis of remaining drug development opportunities
- ✓ Includes Target Product Profile simulator tool based on conjoint analysis



#### **Clarivate DRG Platform Login**

To login to the DRG Clarivate platform, click on - <u>https://authentication.decisionresourcesgroup.com/login/Solutions</u>




\*You may be asked for a password if your company is not integrated with the DRG platform




#### Get started using Disease, Company & Drug Insights Platform

Clarivate" DRG	Welcome       from Clarivate         Jearn more about each product platform. Green check marks indicate partial or full content is available t         Have a ques       2       Please contact us	About Us Contact Us	<b>1.</b> Go to: <u>https://authentication.decisi</u> <u>onresources</u> <u>group.com/login</u>
Understand the Market	Optimize Access	Engage Customers	2.
3 Disease, Company & Drug Insights Disease, Company & Drug Insights Platform Disease Insights Epidemiology Biosimilars Company and Drug Insights Medtech Medtech Market Insights Platform Market Insights (Medtech 360) Brand Tracking (Pricetrack & Marketrack) US Medical Supply Distribution	US Formulary Data & Analytics By Fingertip Formulary Account Management Dashboard Fingertip Accounts Fingertip Alerts Fingertip Analytics Fingertip Home Page (Legacy Platforms) Fingertip Restrictions Fingertip Validation Tool Fingertip PolicyTrack	Sales Enablement © Fingertip Publisher Commercial Targeting © Healthbase © Medtech Insights Platform - Commercial Targeting (Procedure Finder) © Field Force Navigator (FFN) Digital/Multichannel Stakeholder Engagement	Upon login screen, use your work e- mail address and password to login. If you experience any issues, please contact DRG.support@clarivate.com 3.
US Market Access Insights US Market Access Insights Platform - Health Plan Analysis - Market Overviews - Market Overview Interactive Database - National MCO Analyzer - Power Profiles	US Lives Data & Analytics © Employer Vantage (2020 Data) © Employer Vantage (2021 Data) © Integrated Payer Platform © Managed Market Surveyor Suite (Including Pharmacy Benefit Evaluator) Global Market Access	<ul> <li>Digital Insights Platform</li> <li>Multichannel Physician Engagement</li> <li>Multichannel Patient Engagement</li> <li>Multichannel Payer Engagement</li> </ul>	Click on the "Disease, Company & Drug Insights" link.

#### **Disease, Company & Drug Insights Home Page**




#### **Unmet Need Filters Page**



Clarivate

#### **Unmet Need Report**




Clarivate

#### **Target Product Profiles**

At a Glance Landscape & Forecast -	Epidemiology - Current Treatment - Unmet Need - Access & Reimbursement - Geographic Focus: China - Meet The Team		Select Target Product Profil
ble of contents Expand all Search within Content ( Overview Detailed, Expanded Analysis - A	Assessing Drug Development Opportunities To determine the trade-offs across key drug attributes that surveyed physicians are willing to make when considering which treatment to prescribe for first-line metastatic squamous <u>NSCLC</u> , we included an adaptive choice-based conjoint ( <u>ACRC</u> ) module in the survey. Following appropriate analysis, <u>ACRC</u> data allow for the simulation of physician preference share and likelihood to prescribe of user-defined target product profiles ( <u>TRPS</u> ). Conjoint analysis is based on the idea that any product or service is seen by consumers as a combination of attributes or features, each of which contributes to their overall interest in the product or service.	2 Unmet Need - First-Line Metastatic Squamous NSCLC- TPP Simulator - October 2021 Attachment Unmet Need - Metastatic Squamous NSCLC- Executive Summary - October 2021	to review methodology and findings
Metastatic Squamous Non- Small-Cell Lung Cancer (US/EU)	We report on key ACREC analysis findings and one market simulation performed on three hypothetical TEPEs (see the "Conjoint Analysis-Based Simulation of a Market Scenario"). The Excel-based Target Product Profile Simulator allows for the creation of up to seven user-defined TEPEs with varying performance across the attributes included in the survey. To access the Excel-based Target Product Profile Simulator, see the "Downloads" section of the report.	Attachment ADDITIONAL FILES  Detailed, Expanded Analysis -	2. Download Target Product
Introduction Treatment Drivers and Goals Product Performance Against Treatment Drivers and Goals	Through research conducted by Clarivate, we identified six clinical attributes relevant to the assessment of drug development opportunities in the metastatic squamous <u>NSCLC</u> market to be included in our analysis. We included attributes for which there is a high level of unmet need or commercial opportunity and/or are known to be key differentiators of therapies in the metastatic squamous <u>NSCLC</u> market:	Metastatic Squamous Non-Small- Cell Lung Cancer (US/EU) Table of Contents	Profile (TPP) Simulator to run simulations
Assessment of Unmet Need	Median overall survival (months).	🕼 All Tables	
<ul> <li>Target Product Profiles</li> <li>Assessing Drug Development Opportunities</li> </ul>	<ul> <li>Median progression-free survival (months).</li> <li>Objective response rate (% of patients).</li> </ul>		
<ul> <li>Target Product Profile</li> <li>Methodology</li> </ul>	Incidence of grade 3/4 hematological toxicities (% of patients).	Meet the Team	
<ul> <li>Attribute Importance and Part- Worth Utilities</li> </ul>	Incidence of grade 3/4 immune-related adverse events (% of patients).	Pragati Tripathi	
<ul> <li>Conjoint Analysis-Based</li> <li>Simulation of a Market Scenario</li> </ul>	<ul> <li>Incidence of grade 3/4 gastrointestinal toxicities (% of patients).</li> </ul>	Ask the Expert View Bio	
<ul> <li>Appendix</li> <li>Detailed, Expanded Analysis:</li> </ul>	In addition to the six clinical attributes, we included price as an attribute to gauge its influence on physicians' assessment of drug development opportunities.		
EGFR-positive metastatic non- squamous NSCLC (US & EU)	We included three efficacy attributes in our conjoint analysis—median $\Omega_{S}$ , median <u>P.F.S.</u> and <u>Q.R.R</u> —because of their important role in oncologists' prescribing practices and in securing drug approval for metastatic squamous <u>NSCLC</u> . Extending <u>QS</u> is the primary treatment goal for metastatic squamous <u>NSCLC</u> ; therefore, it was not surprising that surveyed U.S. and European medical oncologists both assigned the highest importance score to <u>QS</u> in their treatment decisions (see the section "Treatment Drivers and Goals"). Although <u>QS</u> is considered the gold standard efficacy attribute, we included median <u>P.F.S</u> because a drug's ability to delay disease	View all Experts	

#### **Target Product Profile (TPP) Simulator**

#### Clarivate<sup>®</sup> DRG



The TPP Simulator tool allows you to compare up to 7 TPPs across 6 attributes and 7 price points to gauge which variables influence prescribing behaviors.

Simulator comparisons are based on 2 metrics:

- Preference share the probability that a given TPP in each simulation would be selected
- Prescribing likelihood The likelihood of prescribing projection for each drug is given on a 0% to 100% scale.



#### **Alerts Request**

		1	
Clarivate" DRG Biopharma - Search within Biopharma	Q	≡ Browse All - 🔺 🌢 🛔	1.
Home / My Favorite Topics View My Notifications			To request email alerts of Unmet Need report key updates, select the bell icon
Diseases & Other Topics Medtech		My Favorites	
Q Start typing a disease or topic			<b>2.</b> Select the disease markets
Autoimmune & Inflammation			that you are subscribed to,
Dermatology			select the "Email
Acne	Dermatitis/Eczema		
Actinic Keratosis	Hidradenitis Suppurativa		Preferences" checkbox, then
Alopecia	Psoriasis		select the "Save Settings"
Atopic Dermatitis/Atopic Eczema	Urticaria		button.
Respiratory			
Acute Respiratory Distress Syndrome	Cystic Fibrosis		
Allergic Rhinitis	Idiopathic Pulmonary Fibrosis		
Asthma	Obstructive Sleep Apnea		
Chronic Obstructive Pulmonary Disease	Sarcoidosis	2 Email Preferences	
Rheumatology		Email Preterences	
Axial Spondyloarthritis	Rheumatoid Arthritis		
Juvenile Idiopathic Arthritis	Scleroderma (Systemic Sclerosis)	Save Settings	
Osteoarthritis	Sjogren's Syndrome		

#### **Support Requests**

At a Glance Landscape & Forecast -	Epidemiology 🗸 Current Treatment 🗸 Unmet Need 🗸 Access & Reimbursement 🗸 Geographic Focus: China 🗸 Meet The Team		
	Assessing Drug Development Opportunities		r un teport
ble of contents Expand all Barch within Content O Overview Detailed, Expanded Analysis -  Metastatic Squamous Non- Small-Cell Lung Cancer (US/EU) O Executive Summary	To determine the trade-offs across key drug attributes that surveyed physicians are willing to make when considering which treatment to prescribe for first-line metastatic squamous <u>NSCLC</u> , we included an adaptive choice-based conjoint ( <u>ACBC</u> ) module in the survey. Following appropriate analysis, <u>ACBC</u> data allow for the simulation of physician preference share and likelihood to prescribe of user-defined target product profiles ( <u>TEP</u> s). Conjoint analysis is based on the idea that any product or service is seen by consumers as a combination of attributes or features, each of which contributes to their overall interest in the product or service. We report on key <u>ACBC</u> analysis findings and one market simulation performed on three hypothetical <u>TEP</u> s (see the "Conjoint Analysis-Based Simulation of a Market Scenario"). The Excel-based Target Product Profile Simulator allows for the creation of up to seven user-defined <u>TEP</u> s with varying performance across the attributes included in the survey. To access the Excel-based Target Product Profile Simulator, see the "Downloads" section of the report.	»]	<ul> <li>Unmet Need - First-Line Metastatic Squamous NSCLC- TPP Simulator - October 2021 Attachment</li> <li>Unmet Need - Metastatic Squamous NSCLC- Executive Summary - October 2021 Attachment</li> <li>ADDITIONAL FILES</li> <li>Detailed, Expanded Analysis -</li> </ul>
CRecurve summary     Introduction     Treatment Drivers and Goals     Product Performance Against     Treatment Drivers and Goals     Assessment of Unmet Need	Through research conducted by Clarivate, we identified six clinical attributes relevant to the assessment of drug development opportunities in the metastatic squamous <u>NSCLC</u> market to be included in our analysis. We included attributes for which there is a high level of unmet need or commercial opportunity and/or are known to be key differentiators of therapies in the metastatic squamous <u>NSCLC</u> market: <ul> <li>Median overall survival (months).</li> </ul>		Metastatic Squamous Non-Small- Cell Lung Cancer (US/EU) Table of Contents  All Figures  All Tables
Opportunity Analysis			
<ul> <li>Target Product Profiles</li> </ul>	Median progression-free survival (months).		
<ul> <li>Assessing Drug Development Opportunities</li> </ul>	Objective response rate (% of patients).	1	
<ul> <li>Target Product Profile</li> <li>Methodology</li> </ul>	• Incidence of grade 3/4 hematological toxicities (% of patients).		Meet the Team
<ul> <li>Attribute Importance and Part- Worth Utilities</li> </ul>	• Incidence of grade 3/4 immune-related adverse events (% of patients).		
Conjoint Analysis-Based Simulation of a Market Scenario	Incidence of grade 3/4 gastrointestinal toxicities (% of patients).		Pragati Tripathi Ask the Expert View Bio
O Appendix	In addition to the six clinical attributes, we included price as an attribute to gauge its influence on physicians' assessment of drug development opportunities.		
<ul> <li>Detailed, Expanded Analysis: EGFR-positive metastatic non- squamous NSCLC (US &amp; EU)</li> </ul>	We included three efficacy attributes in our conjoint analysis—median <u>QS</u> , median <u>PES</u> , and <u>QBR</u> —because of their important role in oncologists' prescribing practices and in securing drug approval for metastatic squamous <u>NSCLC</u> . Extending <u>QS</u> is the primary treatment goal for metastatic squamous <u>NSCLC</u> , therefore, it was not surprising that surveyed U.S. and European medical oncologists both assigned the highest importance score to <u>QS</u> in their treatment decisions (see the section "Treatment Drivers and Goals"). Although <u>QS</u> is considered the gold standard efficacy attribute, we included median <u>PES</u> because a drug's ability to delay disease		View all Experts

If you have additional questions or training/support requests, select "Ask the Expert" or "Contact Us" located under the "?" (Resources & updates) icon.

#### Clarivate<sup>™</sup>

### Clarivate<sup>™</sup>

# Have a Question?

DRG.support@clarivate.com clarivate.com

#### **About Clarivate**

Clarivate<sup>™</sup> is a global leader in providing solutions to accelerate the lifecycle of innovation. Our bold mission is to help customers solve some of the world's most complex problems by providing actionable information and insights that reduce the time from new ideas to life-changing inventions in the areas of science and intellectual property. We help customers discover, protect and commercialize their inventions using our trusted subscription and technology-based solutions coupled with deep domain expertise. For more information, please visit clarivate.com.

© 2022 Clarivate. All rights reserved. Republication or redistribution of Clarivate content, including by framing or similar means, is prohibited without the prior written consent of Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.